Publications
Our team is dedicated to the continuing study and education of emerging viruses
![](https://trippbio.com/wp-content/uploads/2023/08/AdobeStock_541064943-1024x614.jpeg)
Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
David E. Martin, Neelam Pandey, Purvi Chavda, Gurpreet Singh, Rakesh Sutariya, Frederic Sancilio, and Ralph A. Tripp
![](https://trippbio.com/wp-content/uploads/2023/08/AdobeStock_332129220-1024x683.jpeg)
Structures of human pannexin-1 in nanodiscs reveal gating mediated by dynamic movement of the N terminus and phospholipids
Maki Kuzuya, Hidemi Hirano, Kenichi Hayashida, Masakatsu Watanabe, Kazumi Kobayashi, Tohru Terada, Md. Iqbal Mahmood, Florence Tama, Kazutoshi Tani, Yoshinori Fujiyoshi, Atsunori Oshima
![](https://trippbio.com/wp-content/uploads/2023/08/AdobeStock_84551447-1024x576.jpeg)
Pannexin-1 channel opening is critical for COVID19 pathogenesis
Ross Luu, Silvana Valdebenito, Eliana Scemes, Antonio Cibelli, David C. Spray, Maximiliano Rovegno, Juan Tichauer, Andrea Cottignies-Calamarte, Arielle Rosenberg, Calude Capron, Sandrine Belouzard, Jean Dubuisson, Djillali Annane, Geoffroy Lorin de la Grandmaison, Elisabeth Cramer-Borde´, Morgane Bomsel, and Eliseo Eugenin
![](https://trippbio.com/wp-content/uploads/2023/08/AdobeStock_70570161-1024x640.jpeg)
Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection
Sarah Rosli, Francis J. Kirby, Kate E. Lawlor, Kate Rainczuk, Grant R. Drummond, Ashley Mansell, Michelle D. Tate
![](https://trippbio.com/wp-content/uploads/2022/07/virus.jpg)
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication
Ralph A. Tripp and David E. Martin
![](https://trippbio.com/wp-content/uploads/2022/08/AdobeStock_185827445-1024x683.jpeg)
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
Sanju Sinha †,‡, Kuoyuan Cheng †,‡, Alejandro A Schäffer ‡, Kenneth Aldape ‡, Eyal Schiff & Eytan Ruppin
![](https://trippbio.com/wp-content/uploads/2022/08/AdobeStock_332450677-1024x768.jpeg)
Probenecid inhibits SARS‑CoV‑2 replication in vivo and in vitro
Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still & Ralph A. Tripp
![](https://trippbio.com/wp-content/uploads/2022/08/AdobeStock_222787795-1024x683.jpeg)
Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy
Olivia Perwitasari, Xiuzhen Yan, Scott Johnson, Caleb White, Paula Brooks, S. Mark Tompkins, Ralph A. Tripp
![](https://trippbio.com/wp-content/uploads/2022/08/AdobeStock_220984578-1024x683.jpeg)
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
Jackelyn Murray, Harrison C. Bergeron, Les P. Jones, Zachary Beau Reener, David E. Martin, Fred D. Sancilio and Ralph A. Tripp
![](https://trippbio.com/wp-content/uploads/2022/08/AdobeStock_329445263-1024x683.jpeg)
The Pathophysiology of COVID-19 and SARS-CoV-2 Infection
Leigh Anne Swayne, Scott R. Johnstone, Chen Seng Ng, Juan C. Sanchez-Arias,
Miranda E. Good, Silvia Penuela, Alexander W. Lohman, Abigail G. Wolpe, Victor E. Laubach, Michael Koval, and Brant E. Isakson